The Fund will seek capital appreciation.
Name | % Net Assets |
---|---|
CELGENE CORP | 9.4% |
GILEAD SCIENCES INC | 7.7% |
GENENTECH INC | 7.1% |
GENZYME CORP-GENERAL DIVISION | 6.5% |
AMGEN INC | 4.6% |
PDL BIOPHARMA INC | 3.9% |
BIOGEN IDEC INC | 3.5% |
VERTEX PHARMACEUTICALS INC | 2.6% |
MYRIAD GENETICS INC | 2.1% |
INDEVUS PHARMACEUTICALS INC | 1.8% |
Key | % Net Assets |
---|---|
CELGENE CORP | 9.4% |
GILEAD SCIENCES INC | 7.7% |
GENENTECH INC | 7.1% |
GENZYME CORP-GENERAL DIVISION | 6.5% |
Other | 69.3% |
Date | n/a |
---|---|
Bid | 0.00 |
Offer | 0.00 |
Currency | n/a |
Change | 0.00 |
% | n/a |
YTD change | 0.00 |
YTD % | n/a |
Fund Inception | 10/07/2000 |
---|---|
Fund Manager | Evan McCulloch / Vincent Xiang |
TER | 1.73 (30-Nov-2011) |
Minimum Investment | |
---|---|
Initial | 1000 |
Additional | 250 |
Savings | 50 |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | -0.14 |
You are here: research